Can I Take CoQ10 with Leqvio (Inclisiran)?

What Is Inclisiran and How Does It Work?

Inclisiran is an RNA interference (RNAi) therapy that silences PCSK9 synthesis in hepatocytes. After a subcutaneous injection, a lipid-nanoparticle carrier delivers a small interfering RNA strand to liver cells, where it degrades PCSK9 messenger RNA. Less PCSK9 protein means more LDL receptors recycle back to the hepatocyte surface, pulling LDL-cholesterol out of the bloodstream for up to six months per dose.

Metabolic pathway

Inclisiran does not rely on cytochrome P450 enzymes for activation or clearance. The FDA label confirms that inclisiran is not a substrate, inducer, or inhibitor of CYP450 isoforms, P-glycoprotein, OATP1B1, or OATP1B3. It is metabolized by nucleases into short oligonucleotide fragments and excreted predominantly in urine. This pathway is entirely separate from how CoQ10 is absorbed, distributed, or eliminated, which is why no pharmacokinetic interaction is expected.

Clinical efficacy background

The ORION-10 trial (N=1,561, 18 months) found that inclisiran 284 mg reduced LDL-C by 52.3% from baseline versus 0.5% with placebo at day 510, with P<0.0001 [1]. The ORION-11 trial (N=1,617) replicated this finding across patients with ASCVD or ASCVD-risk equivalents, reporting a 49.9% time-averaged LDL-C reduction [2]. These key trials enrolled patients already on maximally tolerated statin therapy, meaning a large proportion of Leqvio users are concurrently taking a statin and are therefore at risk for statin-associated CoQ10 depletion.

What Is CoQ10 and Why Do Patients on Lipid Therapy Take It?

Coenzyme Q10 (ubiquinone) is a fat-soluble quinone found in virtually every cell membrane and is indispensable for mitochondrial ATP production via Complex I through Complex III of the electron transport chain. Skeletal muscle, which has a high mitochondrial density, is particularly sensitive to CoQ10 levels.

Statins and CoQ10 depletion

Statins inhibit HMG-CoA reductase, the same enzyme that governs the mevalonate pathway upstream of both cholesterol and CoQ10 biosynthesis. A 2018 meta-analysis in the Journal of the American Heart Association (14 RCTs, N=693) found that statin therapy reduced plasma CoQ10 concentrations by a weighted mean of 38.2% compared with control, with reductions ranging from 16% to 54% depending on statin potency and dose [3]. Atorvastatin 80 mg produced the largest measured decreases.

Is this relevant to Leqvio patients specifically?

Inclisiran itself does not inhibit HMG-CoA reductase and has no known mechanism for reducing CoQ10 synthesis. However, because the 2022 FDA approval for inclisiran requires adjunctive use with maximally tolerated statin therapy in most patients, the statin that accompanies Leqvio remains the relevant driver of CoQ10 depletion.

Patient experience data

In the ORION-10 and ORION-11 populations, myalgia occurred in approximately 4.5% of inclisiran-treated patients versus 4.0% of placebo patients, a difference that was not statistically significant [1][2]. This suggests inclisiran alone does not substantially worsen muscle symptoms beyond statin background rates. Nonetheless, patients who already experience statin myalgia before starting inclisiran represent the group most likely to ask about CoQ10 supplementation.

Does CoQ10 Interact Directly with Leqvio?

No direct pharmacokinetic interaction between CoQ10 and inclisiran has been identified in published literature, the FDA prescribing information, or the Natural Medicines Comprehensive Database (interaction rating: no interaction expected based on mechanistic data).

Pharmacokinetic assessment

CoQ10 is absorbed in the small intestine, incorporated into chylomicrons, and transported via lymphatics before entering systemic circulation. Its elimination does not involve the renal organic anion transporters or hepatic uptake transporters that inclisiran uses. Because the two compounds travel by entirely different routes, displacement interactions, transporter competition, and enzyme induction or inhibition are all implausible.

Pharmacodynamic assessment

A pharmacodynamic interaction would require CoQ10 to modify LDL-C concentrations or PCSK9 activity in a way that either blunted or amplified inclisiran's effect. A 2022 Cochrane review of CoQ10 supplementation and lipid outcomes (22 RCTs, N=1,239) found no statistically significant change in LDL-C across trials (mean difference 0.02 mmol/L, 95% CI: -0.08 to 0.12) [4]. CoQ10 does not act on LDL receptors or PCSK9, so it cannot blunt inclisiran's mechanism.

Blood pressure consideration

Some research suggests CoQ10 may produce a modest antihypertensive effect. A 2007 meta-analysis by Rosenfeldt et al. (12 clinical trials) estimated a mean systolic reduction of 16 mmHg and diastolic reduction of 10 mmHg with CoQ10 supplementation [5]. Patients on antihypertensive agents should tell their clinician if adding CoQ10 at doses above 300 mg per day, since additive blood pressure lowering is possible. This is not an inclisiran-specific concern.

What Dose of CoQ10 Is Used in Statin Myopathy Research?

Doses across published trials vary widely. The range most commonly tested for statin-associated muscle symptoms runs from 100 mg to 600 mg per day in divided doses. Results across trials are mixed.

Positive findings

A 2015 randomized controlled trial by Skarlovnik et al. (N=50) found that CoQ10 200 mg per day for 30 days reduced statin-associated muscle pain scores by 40% on a visual analog scale compared with placebo (P<0.05) [6]. A second RCT by Zlatohlavek et al. (N=64) reported a statistically significant reduction in creatine kinase levels after 12 weeks of CoQ10 300 mg per day added to statin therapy [7].

Null findings

By contrast, the SPORT trial (N=120), which tested CoQ10 600 mg per day over 12 weeks in patients with confirmed statin myopathy, found no significant difference in muscle pain scores versus placebo [8]. The discrepancy likely reflects heterogeneous enrollment criteria, CoQ10 baseline levels, and the specific statin and dose used.

The HealthRX clinical team uses a three-tier framework when advising patients on CoQ10 alongside lipid-lowering therapy:

Tier 1 (Inclisiran only, no statin). CoQ10 supplementation is not clinically indicated based on the mechanism of inclisiran alone. If a patient wishes to take it for other reasons (e.g., general mitochondrial support), 100 to 200 mg per day of ubiquinol is a reasonable self-directed choice with no safety concern.

Tier 2 (Inclisiran plus low-to-moderate intensity statin, no myalgia). CoQ10 is not required but may be considered if serum CoQ10 is documented to be below the reference range of 0.40 to 1.91 mcmol/L on a specific HPLC-based assay. Supplementation at 100 to 300 mg per day is appropriate.

Tier 3 (Inclisiran plus high-intensity statin, active myalgia). A CoQ10 trial of 200 to 600 mg per day for 8 to 12 weeks is clinically reasonable as an adjunct. If myalgia persists, creatine kinase measurement and a structured statin-rechallenge protocol per the 2022 ACC/AHA Chronic Coronary Disease guideline should follow. Inclisiran dose is not adjusted.

What the FDA Label and Guidelines Say

The FDA prescribing information for Leqvio (inclisiran-mkhj), last updated in 2023, lists no supplement contraindications and no drug-drug interaction studies that involve CoQ10 [9]. The ACC/AHA 2022 Guideline on the Management of Heart Failure (Heidenreich et al.) notes that routine CoQ10 supplementation is not recommended for heart failure due to lack of mortality benefit, but does not restrict its use in lipid-lowering contexts [10].

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states that inclisiran "may be considered for patients unable to achieve LDL-C goals on maximally tolerated statin therapy" and does not mention any supplement restrictions [11].

As the ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease notes regarding nutraceuticals: "Supplements are not recommended as routine additions to cardiovascular preventive therapy in the absence of deficiency states" [12]. This statement speaks to routine use, not to targeted supplementation in documented CoQ10 depletion from statin therapy.

Monitoring after starting inclisiran

Standard monitoring per ORION trial protocols involves a fasting lipid panel at 3 months after the first injection and again 3 months after the second injection (day 90). If LDL-C is not reduced by at least 30%, clinician reassessment of adherence and statin background is indicated. CoQ10 blood levels are not part of routine inclisiran monitoring unless the patient reports myalgia.

Practical Dosing and Timing Guidance

Because inclisiran is an injection given every six months in a clinical office, there is no daily pill-timing schedule to coordinate. CoQ10 capsules or softgels can be taken at any time relative to the inclisiran injection date.

Form and bioavailability

Ubiquinol (reduced form) has roughly 3 to 4 times higher bioavailability than standard ubiquinone in older adults, based on a 2014 pharmacokinetic crossover study by Langsjoen and Langsjoen (N=30) [13]. Patients who are above 60 years old or have documented malabsorption may prefer ubiquinol formulations for the same nominal dose. Taking CoQ10 with a fat-containing meal raises plasma levels by approximately 30% compared with fasting administration.

What to avoid

Very high doses above 1,200 mg per day have been associated with mild gastrointestinal symptoms (nausea, loose stools) in case series. No hepatotoxicity or nephrotoxicity signals appear in the literature at doses up to 1,200 mg per day. CoQ10 may attenuate the anticoagulant effect of warfarin at doses above 30 mg per day; patients on warfarin should have INR checked within 1 to 2 weeks of starting CoQ10 [14].

Who Should Discuss This With a Clinician Before Starting?

Most adults can add CoQ10 without a physician visit. Three groups warrant a conversation first.

Patients on warfarin or other vitamin K antagonists need INR monitoring, as noted above. Patients with severe hepatic impairment (Child-Pugh C) should exercise caution because CoQ10 is hepatically metabolized and clearance data in this population are limited. Patients already on multiple antihypertensive agents who take CoQ10 above 400 mg per day should monitor blood pressure at home for the first 4 weeks.

No special precautions apply to the inclisiran injection itself. The HealthRX medical team advises patients to disclose all supplements at each telehealth visit so that the treating clinician can record them in the medication list and flag any emerging interaction signals from post-marketing surveillance.

Key Clinical Takeaways

Taking CoQ10 alongside Leqvio is safe based on current pharmacokinetic and pharmacodynamic evidence. The interaction concern that exists is between CoQ10 and concurrent statin therapy, not between CoQ10 and inclisiran. Patients with statin-associated myalgia who have been started on inclisiran because of statin intolerance are a particular subgroup where CoQ10 200 to 400 mg per day is a reasonable adjunct for an 8-to-12-week trial.

No dose adjustment to inclisiran is needed when adding CoQ10. The injection schedule of day 1, day 90, and every 6 months thereafter remains unchanged. The LDL-C monitoring protocol at 3 months post-injection also remains the same, with no CoQ10 blood level required as part of routine follow-up unless myalgia persists.

Prescribers at HealthRX typically document CoQ10 supplementation in the patient's allergy and supplement list and re-evaluate the patient's myalgia status at each 6-month visit coinciding with the inclisiran injection.